Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
1.310
-0.105 (-7.42%)
At close: Dec 12, 2025, 4:00 PM EST
1.280
-0.030 (-2.29%)
After-hours: Dec 12, 2025, 7:59 PM EST
Senti Biosciences Employees
Senti Biosciences had 34 employees as of December 31, 2024. The number of employees decreased by 14 or -29.17% compared to the previous year.
Employees
34
Change (1Y)
-14
Growth (1Y)
-29.17%
Revenue / Employee
n/a
Profits / Employee
-$1,473,618
Market Cap
34.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34 | -14 | -29.17% |
| Dec 31, 2023 | 48 | -74 | -60.66% |
| Dec 31, 2022 | 122 | 33 | 37.08% |
| Dec 31, 2021 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SNTI News
- 3 days ago - Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 3 days ago - Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile - GlobeNewsWire
- 8 days ago - Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET - GlobeNewsWire
- 4 weeks ago - Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December - GlobeNewsWire
- 5 weeks ago - Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference - GlobeNewsWire
- 2 months ago - Senti Bio to Present at BioJapan - GlobeNewsWire
- 3 months ago - Senti Bio to Present at the MedInvest Biotech & Pharma Conference - GlobeNewsWire